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ABSTRACT 
Natural and synthetic biomaterials have been widely used in tissue engineering applications, 
but these materials lack the functional, mechanical, biological and structural complexity of 
natural extracellular matrix (ECM). Because reaching such complexity with ECM substitutes 
is very challenging, using the natural ECM itself as biomaterial in tissue engineering 
applications has gained much interest. As remnant cellular content from allogenic or xenogenic 
sources could cause unwanted host response, ECM needs to be decellularized before being used 
as biomaterial.  
 Conventional tissue engineering approaches do not exhibit the necessary complexity and 
precision, and hence 3D bioprinting is used to create 3-dimensional structures with desired 
complexity and precision. Up to now, many biomaterials have been used as bio-inks for 3D 
bioprinting, but as they lack the necessary complexity, there is a need for novel bioinks. 
Decellularized extracellular matrix (dECM) is a great candidate to be used as bioink in 3D 
bioprinting as it provides the necessary microenvironments during and after bioprinting if it can 
be processed into a printable form.  
This thesis work aims to create a novel bioink by combining cell sheet derived decellularized 
extracellular matrix (dECM) with a natural hydrogel, agarose. The cell sheets were 
decellularized and characterized before used as a bioink. The decellularization protocol and its 
effects on the structure of the extracellular matrix were evaluated. The dECM was solubilized, 
neutralized, mixed with 3T3 fibroblast cells and agarose before bioprinting. The blend bioink 
was bioprinted and cultured for a week. The results showed that the developed decellularization 
protocols were successful in terms of cellular removal and structural preservation. Also, the 
hybrid bioink provided an appropriate environment for cellular viability and microenvironment. 
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ÖZET 
Doğal ve sentetik biyomalzemeler doku mühendisliği uygulamalarında günümüze kadar 
sıklıkla kullanılmış olsa da, bu malzemeler doğal ekstrasellüler matriksin sahip olduğu 
fonksiyonel, mekanik, biyolojik ve yapısal özellikleri taşımamaktadır. Alternatif malzemelerle 
bu özelliklere ulaşmak zor olduğundan, ekstrasellüler matriksin kendisi, doku mühendisliği 
uygulamalarında kullanmaya başlamıştır. Ekstrasellüler matriks, biyomalzeme olarak 
kullanılmadan önce hücresel içeriğinden arındırılmalıdır. Böylelikle, allojenik veya zenojenik 
kaynaklardan gelebilecek, istenmeyen reaksiyonlar önlenmiş olur. 
Geleneksel doku mühendisliği yöntemleri, ihtiyaç duyulan hassasiyeti ve özellikleri 
taşımadığından, 3-boyutlu biyobasım yöntemi bu sorunları aşmak amacıyla sıklıkla 
kullanılmaktadır. Günümüze kadar pek çok malzeme, biyomürekkep olarak kullanılmış olsa 
da, arzu edilen özelliklere ulaşmadıklarından yeni biyomürekkeplere ihtiyaç duyulmaktadır. 
Hücresizleştirilmiş ekstrasellüler matriks, sahip olduğu özellikler nedeniyle biyomürekkep 
olarak kullanılmak için uygun bir adaydır. 
Bu tez çalışmasında, hücre tabakası yöntemi ile üretildikten sonra hücresizleştirilmiş 
ekstrasellüler matriks yapılarını agaroz ile karıştırarak yeni biyomürekkep üretimi 
amaçlanmıştır. Hücresizleştirme yöntemlerinin üretilen yapılar üzerindeki etkileri ve yöntemin 
hücre uzaklaştırmadaki başarısı değerlendirilmiştir. Elde edilen yapılar, jelleştirilmiş, nötralize 
edilmiş, agaroz ve 3T3 fibroblast hücreleri ile karıştırılarak biyobasımları gerçekleştirilmiştir. 
Biyobasım sonrasında 1 haftalık inkübasyon gerçekleştirilmiştir. Alınan sonuçlar, geliştirilen 
hücresizleştirme yöntemlerinin hücre uzaklaştırmada başarılı olduğunu ve malzemenin 
yapısına zarar vermediğini göstermiştir. Ayrıca, üretilen biyomürekkebin hücre canlılığı için 
uygun ortam sağladığı olduğu görülmüştür. 
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1. INTRODUCTION 
1.1. Biomaterials Used In Tissue Engineering 
As the life quality and lifespan of humankind increases, there is a growing need for organ and 
tissue transplantation. Even though there are major improvements on transplantation 
technologies and the success of the procedure is higher than ever, there are not enough donors 
to fulfill this growing need. Only one-third of the patients are lucky enough to receive matching 
organs or tissues from donors [1]. Therefore, there is an urgent need to create new tissues and 
organs which are not sourced from a donor. This can be achieved by using tissue engineering 
which is a multidisciplinary field combining medicine, engineering, material science and 
biology, focusing on the regeneration, repair, and replacement of tissues and organs which are 
damaged, diseased or malfunctioning [2], [3]. In order to create tissue-engineered organs and 
tissues, the appropriate biomaterials need to be used. To date, there has been a various number 
of materials, synthetic or naturally derived, used for this purpose. In the following sections, 
examples of such materials are explained in details. 
1.1.1. Synthetic biomaterials used in tissue engineering 
Synthetic biomaterials such as polycaprolactone, polyethylene glycol, polylactic acid and 
polyglycolic acid have been used for tissue engineering applications. Synthetic materials have 
the advantage of being reproducible [4]. They have good mechanical properties, and their 
properties can be well controlled during their production but, they usually lack the requisite 
biological cues and signaling molecules [4]. 
Poly(ethylene glycol) (PEG) is a biocompatible material which is created by the polymerization 
of ethylene oxide [5], [6]. It has strong mechanical properties, is not toxic or immunogenic but 
 2 
is bioinert therefore is widely used as blends with bioactive materials [6]. This biomaterial was 
approved by Food and Drug Administration for biomedical use [7]. 
Polycaprolactone (PCL) is a synthetic biomaterial used widely for a variety of tissue 
engineering applications such as mechanical support for bioprinting applications. PCL has 
biocompatible and non-toxic properties, therefore, is widely preferred [7]. 
Polylactic co-glycolic acid (PLGA), which is copolymer of poly glycolic acid and poly lactic 
acid, is a biocompatible synthetic biomaterial used for tissue engineering applications. During 
bioprinting applications, PLGA is used as a paper for stacking the cells [7], [8]. 
1.1.2. Natural biomaterials used in tissue engineering 
Unlike synthetic biomaterials, natural biomaterials, also called hydrogels, have weak 
mechanical properties. The properties of natural materials vary based on their batch [9]. They 
contain biological cues which are crucial for the biocompatibility and bioactivity of the 
biomaterial. Examples of naturally derived biomaterials, used in tissue engineering applications 
are alginate, collagen, gelatin, and chitosan. 
Agarose is a natural biomaterial which is classified based on its melting temperature. 
Depending on the hydroxyethylation of the material, its melting temperature changes [10]. Low 
melting temperature agarose is widely used in extrusion-based bioprinting applications as it 
gels at temperatures around 26- 30 °C [11]. Agarose is not a bioactive material and does not 
support cell adhesion, but it has the potential to be used as a blend with other materials. Agarose 
has been used blended with collagen for extrusion-based bioprinting applications [12]. 
However, agarose cannot be used with inkjet bioprinting as its low viscosity may lead to the 
clogging of the nozzle [13]. 
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Alginate, or alginic acid, is a natural biomaterial derived from brown seaweed and is used for 
3D bioprinting, especially for extrusion-based bioprinting applications due to its printability, 
biocompatibility, low cost, tunable viscosity, low toxicity and rapid gelation [5], [14], [15]. Due 
to its rapid gelation feature, alginate has good printability [6]. Unfortunately, alginate is a 
bioinert material, that is, due to its hydrophilic nature cells cannot interact with the material and 
cell proliferation, as well as migration, is limited [5]. 
Chitosan is a non-toxic, antibacterial and antifungal natural biomaterial widely used for wound 
healing purposes [6]. Chitosan has biodegradable properties, but it lacks mechanical strength, 
and hence, it is widely used as blends with other biomaterials [5].  
Collagen is the most abundantly found protein in the animals [6]. Due to its arginine-glycine-
aspartic acid (RGD) amino acid sequence, it helps cell attachment and proliferation, therefore, 
can be used as tissue scaffolds [16], [17], [4], [15]. When collagen is degraded hydrolytically, 
the resulting product is gelatin [18]. Gelatin is a biocompatible and non-immunogenic 
biomaterial which can be degraded completely in vivo [19]. It has low antigenicity, low cost 
and also contains RGD amino acid sequence which makes it a successful material for tissue 
engineering and cell attachment [20]. It is widely used for bioprinting applications in the form 
of Gelatin methacrylate (GelMA) which is a modified version of gelatin that can crosslink with 
UV light and has mechanical strength [21]. 
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1.2. Extracellular Matrix (ECM) 
Those synthetic and natural materials mentioned before lack the functional, mechanical, 
biological and structural complexity of natural extracellular matrix (ECM) therefore they 
cannot provide necessary cues to perfectly recapitulate the functions and structure of native 
tissues and organs [22]. As reaching such complexity with ECM constituents is very 
demanding, the solution is to use the natural ECM itself as a biomaterial for the tissue 
engineering applications. 
1.2.1. Sources of ECM 
1.2.1.1. Tissue-derived ECM 
ECM derived from tissues have different properties based on the tissue of origin. As every 
tissue has their unique properties, the strengths and weaknesses of ECM obtained from different 
tissues are different. Therefore, the ECM should be obtained from a certain tissue depending 
on the requirement of use. ECM obtained from tissues are abundant in amount, but there are 
some drawbacks that lead scientists to prefer cell-derived ECM. Such drawbacks are the 
dependence of composition and structure of the material to the condition of the tissue source, 
the risk of pathogen transfer and unwanted host responses [23]. 
As can be seen in Figure 1, ECM derived from tissues can be further processed into different 
structures such as hydrogel, foam, fiber or they can be 3D printed. In order to produce 
hydrogels, ECM is first processed into particles. Then, with the help of digestive enzymes such 
as pepsin, it is digested and solubilized into hydrogel form. Same steps can be applied for foam 
formation. ECM fibers, on the other hand, are produced by electrospinning [24].  
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Figure 1: Processing of ECM derived from tissues (A) ECM-based hydrogel scaffolding, (B) ECM-
based electrospinning, (C) Tissue 3D bioprinting [24] 
1.2.1.2. Cell culture and cell sheet derived ECM 
Although tissue-derived ECM has its advantages, the risk of pathogen transfer and host 
responses are great drawbacks. The ECM obtained from allogenic tissue sources might induce 
pathogen transfer while xenogenic ECM might cause unwanted host response [25]. In order to 
overcome these drawbacks and have a safer approach, ECM could be obtained from cell culture. 
Cell-derived ECM reduce the risks of tissue derived ECM to a minimum and also has the 
advantage of great control over the product as cell-derived ECM properties can be altered by 
using different cell types, culture media, and culture systems as well as adding different 
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substrates. Moreover, the cell culture can be screened against pathogens. Autologous cells can 
be utilized as a cell source, which means overcoming the donor shortage problem [26], [27]. 
Another advantage of cell-derived ECM is ease of decellularization. The shortcomings of the 
cell-derived ECM are the long culture periods, increased cost due to the long culture period and 
weak mechanical properties [24]. Cell culture derived ECM can be used in many different forms 
for many different applications as can be seen in Figure 2.  
Cell sheets can also be used as extracellular matrix sources and are created by culturing the cell 
types of interest for a long time, frequently on a thermo-responsive surface such as 
polydimethylsiloxane (PDMS) in order to easily remove the sheet from the surface with 
temperature variations. Cell sheets are dense stacks of cells created by long culture periods, and 
they possess an intact cell to cell attachment surrounded by the secreted extracellular matrix 
[28]. Cell sheets are removed from the surface without the use of proteolytic enzymes, 
therefore, their structure and integrity are preserved. Cell sheets possess many advantages such 
as controllable production period, ease of manufacturing and processing. Cell sheets can be 
created without the help of scaffolds and be transplanted without destructive applications such 
as suturing [29]. Cell sheet technology has been used for myocardial tissue engineering, corneal 
surface reconstruction, and periodontal applications [30]. The main drawback of cell sheet 
creation is the long culture period which leads to increased cost and contamination risk [24]. 
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Figure 2: Processing of ECM derived from cell culture (A) ECM surface modification, (B) 
ECM scaffold from resolvable polymer master, (C) Cell sheet assembly [24] 
1.2.2. Structure, functions, and applications of ECM as a biomaterial 
The structure of ECM varies among tissues in a way that every tissue has different ECM 
structure providing the necessary microenvironment for the maintenance of the cells, a concept 
called organ specificity [31, 32]. Regardless of the tissue type, ECM structure is always 
composed of polysaccharides, proteins, growth factors and cytokines as shown in Figure 3. 
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Figure 3: ECM structure, summarized [33] 
Proteins found in ECM can have fibrous properties or adhesive properties. Fibrous proteins 
such as collagen and elastin provide structural support, elasticity and mechanical integrity to 
ECM while adhesion proteins such as fibronectin, laminin, and integrin keep other components 
of ECM intact and avail in cell proliferation, adhesion, and migration [24], [33]. 
Glycosaminoglycans are linear polysaccharides which carry a negative charge on their sulfate 
or carboxyl group, and hence, they can hold water molecules. This property provides 
mechanical stability to ECM and also engineered tissues as well [34].  
ECM has a dynamic nature and responds to changes happening in the surrounding 
microenvironment. Its composition and activity change according to the environmental 
conditions and this concept is called dynamic reciprocity [35]. ECM influences cell 
differentiation, migration, proliferation [36]. 
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ECM can be used in a reconstructive manner for tissue and organ engineering. As summarized 
in Table 1, examples of ECM biomaterials obtained from different tissues and used in 
commercial scale can be given as Allodermâ obtained from human dermis, SurgiSISâ and 
Restoreâ obtained from porcine small intestinal soft mucosa, and Synergraftâ obtained from 
porcine heart valves [37].  
Table 1: Commercial ECM products [36] 
 
ECM can be used as a scaffold to host different cell types such as stem cells [26], or as a grafting 
material. The sacrificial cells which are programmed to death are allowed to secrete ECM 
before their death. Removal of the cells results into a porous ECM graft which can be further 
seeded with autologous cells [38], [27]. ECM has been used in combination with other materials 
in order to increase the mechanical strength and stability. To date, materials such as 
glutaraldehyde, genipin, and vitamin B2 were used combined with ECM for this purpose [24]. 
ECM materials have been used for stem cell differentiation as well, and it has been proven that 
ECM biomaterials have positive effects on stem cell differentiation [39]. 
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1.2.3. Production steps of ECM biomaterials 
ECM is obtained from tissues or cell cultures and needs to be processed before it can be used 
as a biomaterial. Such processes are usually composed of several steps that can be exampled as 
but not limited to decellularization, grinding, solubilization and neutralization. The ECM can 
be fabricated into hydrogel in various forms suach as foam,  electrospinning into fibers or 3D 
bioprinting into more complex structures.  
1.3. Decellularization Process 
Decellularization is the removal of cellular content from tissues and organs, or as in our case, 
from the ECM structure created by the cell sheets. Decellularization can be achieved by the use 
of chemical or biological agents as well as by physical methods and is a crucial step in ECM 
biomaterial production. 
Up to now, many tissues and organs such as bladder, heart valve, dermis, placenta, liver, lung 
and kidney have been decellularized [35]. Many different species such as mice, rats, pigs were 
used as tissue sources for decellularization [32]. Decellularization gains interest among 
researchers as it expands horizons for tissue engineering applications. An interesting example 
is the production of heart tissue by decellularization and recellularization of spinach tissue [40]. 
1.3.1. Purpose of decellularization and success criteria in decellularization  
The cellular content of ECM has the potential to cause host response when grafted, therefore, 
has to be removed before grafting. DNA and Gal-epitope are two main reasons why host 
response may occur. Gal epitope, oligosaccharide α-Gal (Galα1,3-Galβ1–4GlcNAc-R), is a cell 
membrane antigen present in all species except for Old World Monkeys and humans. As 
humankind do not have this antigen, the transplantation of a xenograft leads to a host reaction, 
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causing rejection of the graft. Therefore, the Gal epitope present on the xenografts needs to be 
removed before grafting [41].  
As remnant DNA in the graft can cause inflammatory reactions in the host, the DNA has to be 
removed during decellularization. Another reason why DNA needs to be removed is that it 
causes calcification after implantation [35]. However, as most of the tissues are dense stacks of 
ECM and DNA, it is almost impossible to remove 100% of the DNA. Therefore, the remnant 
DNA after decellularization should be quantitatively examined, or qualitative examinations 
should be done, i.e. there should be no image obtained after 4',6-diamidino-2-phenylindole 
(DAPI) or hematoxylin and eosin (H&E) staining [36], [35]. The intracellular and cell 
membrane components of the cells need to be removed as well. Also, the remnant 
decellularization agents and immunologically active molecules are unwanted as they might 
cause toxicity or host response [26], [35]. 
Although the main aim of decellularization is the removal of the cellular content, preserving 
the ECM structure and composition is also important. Maximum removal of cellular content 
should be achieved while minimum damage caused to the ECM network. Mechanical strength 
and compositional integrity of the ECM structure need to be preserved [32].  
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1.3.2. Decellularization techniques 
There are two main techniques of decellularization; immersion and perfusion methods. 
Depending on the type and the structure of the tissue of interest the appropriate technique should 
be chosen. Immersion is used when the tissue being decellularized is non-vascular while 
perfusion requires the vascular system for the perfusion of the decellularization agent. 
Immersion is applied to small, thin tissues while perfusion can be used for large tissues and 
organs [32]. Immersion is usually applied in combination with agitation for better diffusion of 
the decellularization agents to the tissue being decellularized [32]. 
1.3.3. Decellularization methods 
All decellularization methods are based on four main steps. The first step of decellularization 
is to lyse the cell membrane as a preparation for the upcoming steps. This can be achieved by 
physical applications or by using chemicals which target the cell membrane. The second step 
of decellularization is the separation of cellular content from ECM structure. The third step is 
the solubilization of the separated cellular content. The final step is the removal of the cellular 
content from ECM structure. There are three main methods for decellularization: use of 
chemical agents, use of biological reagents and the use of physical methods [37]. As all these 
different methods have their advantages and disadvantages, using combinations of these 
methods is considered as a solution for more successful decellularization. 
The selection of the appropriate method for decellularization of a certain tissue or organ 
depends on several variables such as the cellular content of the tissue, density and thickness of 
the tissue, the objective application and the desired biological and mechanical properties of the 
final product [26], [36]. 
 13 
1.3.3.1. Chemical methods 
Chemical methods can effectively remove the cellular content, but at the same time, they cause 
loss of collagen content, and damage to the ECM structure and mechanical strength [42], [35]. 
Chemical agents used for decellularization are; alkaline or acid solutions, ionic detergents, non-
ionic detergents and zwitterionic detergents [42]. Alkaline or acid solutions hydrolyze the 
cellular content and degrade the nucleic acids [26]. Sodium dodecyl sulfate (SDS) is the most 
commonly used ionic detergent for the successful removal of cellular content of thick tissues. 
Other ionic detergents used for decellularization are sodium deoxycholate and Triton X-200 
[36]. Among non-ionic detergents, Triton X-100 is the most commonly used one as it provides 
a successful removal of cellular content. The success of Triton X-100 depends on the type of 
the tissue. Triton X-100 was shown successful for decellularization of thin tissues such as heart 
valve and blood vessel [43], [26] but unsuccessful for the decellularization of the tendon which 
is connective tissue. Zwitterionic detergents show properties of both ionic and non-ionic 
detergents [44]. These detergents are used for decellularization of thin tissues. 
1.3.3.2. Biological (Enzymatic) methods 
Enzymatic methods are known to remove the cellular content successfully and preserving the 
collagen while harming the ECM structure [37]. Biological agents used for decellularization 
include proteolytic enzymes, chelating agents and nucleases [26]. Chelating agents such as 
ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA) have 
deleterious effects on protein-protein interactions which help to ease the decellularization 
process. Biological methods need to be used in combination with other decellularization 
methods [36]. 
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1.3.3.3. Physical methods 
Physical methods such as abrasion, sonication, and freeze-drying are useful for the disruption 
of the cellular membrane, and as no chemicals are used during physical decellularization 
methods, the risk of toxicity is eliminated. Unfortunately, this method cannot remove the 
cellular content completely without repetitions of the procedure which may cause the loss of 
protein components [35]. Therefore, the combination of physical methods with chemical and 
biological methods is required for complete decellularization.  
1.4. 3D Bioprinting 
There are many different conventional methods used for tissue engineering applications such 
as electrospinning, melt-molding, and freeze-drying which do not provide sufficient precision 
over internal and external geometry as they have control only on the bulk properties of the 
product [45]. Therefore, there is a great need for improved manufacturing methods which can 
reach the desired complexity and functionality. Three-dimensional bioprinting, an additive 
manufacturing method, which can overcome the problems of conventional methods, is used for 
the creation of such tissue constructs.  
Three-dimensional bioprinting is the computer-aided fabrication of biological materials in a 
layer by layer manner with controlled positioning, mechanical and structural precision. The aim 
is creating three-dimensional tissue and organ constructs which are utilized in different fields 
such as tissue engineering, drug discovery, cancer research and surgical training [46]. There are 
multiple steps of 3D bioprinting which can be classified into three main stages as pre-process, 
process and post-process [47]. The first step in the pre-processing stage is the design of the 
geometry to be printed out. The structure to be printed out can be obtained by medical imaging 
techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) in order 
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to increase the accuracy of the geometry of the product. Then, the obtained image is processed 
into a computer model. The generated design is sliced, and path plans are generated for each 
layer. The cell types and materials suitable for the targeted tissue are then selected. The printing 
stage is conducted with the help of computer control which increases the quality of the printed 
structure. The three-dimensional organization is obtained by stacking layers of two-
dimensional structures where the thickness of the layers represents the resolution of the system. 
Lastly, during the post-process stage, the printed structure is taken into a bioreactor or an 
incubator for further maturation [48, 49]. 
1.4.1. Bioprinting methods  
There are multiple acellular printing methods such as stereolithography, solid freeform 
fabrication and powder-fusion printing [50], but our main emphasis here is on the cell and 
biological material based bioprinting methods. 
There are many different bioprinting methods mostly varying based on forming layers. Most 
commonly used bioprinting methods are extrusion based, droplet-based (inkjet) and laser-based 
bioprinting methods which are summarized in Figure 4. For successful bioprinting, a bioprinter 
should be affordable, have high resolution, full automation, user-friendliness, ease of 
sterilization and appropriate size [51]. Also, the printed structure should have shape fidelity, 
high resolution and the ability to preserve integrity when incubated with the culture medium 
after printing [52]. The environmental conditions such as temperature, humidity, sterilization 
at which the printing is being held are also important. 
 16 
 
Figure 4:  3 main bioprinting methods summarized, (a) Micro-extrusion printer, (b) Inkjet 
printer, (c) Laser direct writing [53] 
 
1.4.1.1. Extrusion-based 3D bioprinting 
Extrusion-based bioprinting is the most popular, affordable and commercially available method 
of bioprinting due to its ability to print out a various number of materials and cell-friendly 
printing conditions [53]. 
During extrusion based or in other words pressure assisted 3D bioprinting, the material of 
interest is deposited out of the printer with the help of pressure application which is created 
pneumatically with an air-force pump or mechanically with mechanical screw plunger [13], 
[49]. 
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The range of viscosity of the materials that are printed out with this method is very wide. Also, 
materials with high cell density can be printed out successfully with extrusion-based bioprinting 
[49]. The cell viability after printing is commonly high, very little harm is made to the cells. 
With extrusion based bioprinting, porous structures can also be printed [5]. The printed 
materials can be crosslinked chemically, thermally or with light [1]. Downsides of this method 
are the relatively low resolution which is around 100 µm and the low bioprinting speeds [54], 
[4], [50]. 
Most of the commercial bioprinters are extrusion based bioprinters; examples are; Bioplotter of 
EnvisionTec, NovoGen 3D Bioprinting Platform of Organovo [49], 3D Discovery by RegenHU 
as shown in Figure 5. 
 
Figure 5: Widely used commercial bioprinters. (a) NovoGen 3D Bioprinting Platform of 
Organovo, (b) Bioplotter of EnvisionTec, (c) 3D Discovery by RegenHU [47] 
1.4.1.2. Droplet-based 3D bioprinting 
Droplet-based 3D bioprinting, also called drop-by-drop or drop-on-demand bioprinting,  is a 
bottom-up process that creates three-dimensional structures by droplets of bioink generated 
hydrodynamically, acoustically, mechanically, electrically or thermally [4]. The most common 
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ways of generating the droplets are electrical and thermal manners which are classified under 
inkjet bioprinting [13]. During inkjet bioprinting, the bioink droplets can be generated with the 
help of electric charge application which leads to the vibration of piezoelectric material that 
forms pressure to thrust the bioink out of the nozzle in the form of droplets. This conversion 
between electric charge application and pressure outcome is considered as piezoelectric 
conversion. Another way to generate droplets is by application of temperature which leads to 
expansion of air bubbles and therefore, pressure increase that pushes the droplets out of the 
nozzle [55]. Inkjet bioprinting is the first ever used bioprinting method which originated from 
office type commercial inkjet printers. 
In droplet-based bioprinting, the droplet volume is usually in the range of picolitres. The 
advantages of such systems include high resolution, ability to print materials with low viscosity, 
low cost, high printing speed and high cell viability [53], [49]. Also, as this is a non-contact 
method, where the nozzle and the surface that the printing is done on has no contact, the risk of 
contamination is reduced [47], [56]. 
Bioinks used in inkjet-based bioprinting needs to have low viscosity to be suitable for low force 
applications and avoiding clogging [52], [56]. As this printer requires low viscosity materials, 
the mechanical strength of the printed structures is relatively low [4]. Working with low 
viscosity materials also means that the deposition of ECM is challenging [57]. Inkjet bioprinters 
require temperature application which can cause stress on the cells leading to a decrease in cell 
viability [47].  One major drawback of inkjet bioprinters is the settling effect. At the beginning 
of the bioprinting process, the bioink is in a homogenous condition, but as the time passes, with 
the effect of gravity, cells tend to accumulate at the lower levels of the cartridge which disturbs 
the homogeneity and results in clogging of the printer head [58]. 
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1.4.1.3. Laser-based 3D bioprinting 
Laser-based 3D bioprinters are comprised of three main parts. The pulsed laser, the ribbon and 
the receiving substrate [59]. The pulsed laser helps to create the force that propels the material 
to the receiving substrate through the ribbon which can be considered as an energy absorbing 
slide [60], [49]. There are two main methods of laser-based 3D bioprinting: absorbing film-
assisted laser-induced forward transfer (AFA-LIFT) and matrix-assisted pulsed laser 
evaporation direct writing (MAPLE-DW). The main difference between these methods is the 
ribbon, in the latter method, there are two layers of ribbons [60]. Laser-based printing has the 
advantage of reducing the risk of contamination as the nozzle of the printer does not contact the 
surface on which the printing is completed. This non-contact working conditions also result in 
increased cell viability due to little mechanical stress applied to the cells [49]. The precision 
and resolution are high for laser-based 3D bioprinting method [50]. Unfortunately, this system 
is costly and not cell friendly because of the laser beam. The laser beam is harmful to the cells 
and, the heat generated by the laser is another problem for cell viability.   
The three methods of bioprinting are summarized in Table 2 based on most important 
parameters such as cost, cell viability, and resolution. The appropriate method of bioprinting 
needs to be selected based on the needs of the research and applications of the final construct. 
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Table 2: Advantages and disadvantages of different bioprinting methods summarized [4] 
 
 
1.5. Bioinks used for 3D Bioprinting Applications 
Bioink is the material that is printed out during 3D bioprinting applications. Bioinks are 
composed of cells, biomaterials, support materials and bioactive cues. Depending on the 
preferred bioprinting method and the desired properties of the product, the suitable bioink needs 
to be selected.  
The bioinks used in 3D bioprinting needs to possess several properties such as printability, 
bioactivity, biocompatibility, mechanical durability, affordability, scalability, biodegradability 
and their microenvironment should support cell attachment, viability and proliferation in order 
to recapitulate the native tissues and organs [46], [42], [13], [52]. A bioink that is printable 
should have a large contact angle with the printing substrate. It also needs to possess tension in 
the vertical direction in order to keep its integrity and three-dimensional structure after the 
printing process [49]. A biocompatible bioink does not cause unwanted host reactions like 
immune response while the bioactive bioink can generate required biological responses. 
Mechanical durability means that the bioink is stable during and after transplantation [49].  
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Moreover, bioinks should not be affected by the post-printing conditions such as incubation 
with cell culture medium [13]. Bioinks should allow the transportation of nutrients and water 
as well as removal of wastes [24]. The material to be printed needs to be in aqueous or aqueous 
gel form in order to provide the best environment for the cells [61]. All these criteria reduce the 
number of the possible materials which can be used for bioprinting. There is still a need to 
develop new biomaterials that can fulfill the criteria above for successful, safe and efficient 
bioprinting. The selection of the material to be used is based on the desired properties of the 
final product. 
1.5.1. dECM as bioink for 3D bioprinting applications 
The success of dECM as bioink was shown when dECM derived from cartilage and adipose 
tissues were solubilized and bioprinted into PCL supporting scaffold while dECM derived from 
heart tissue was bioprinted without a supporting scaffold [22]. As shown in this study, dECM 
requires to be mixed with a mechanically stable, strong but bioinert material for mechanical 
success while dECM itself has the potential to improve the cellular functions such as migration, 
maturation, and differentiation [22]. Later on, more studies were conducted on the use of dECM 
as bioink. Skeletal muscle-derived dECM was used as bioink in order to fabricate skeletal 
muscle constructs. As most components of ECM were preserved and constructs provided 
appropriate support for cell viability, the skeletal muscle-derived dECM was concluded as a 
successful bioink [62]. 
Furthermore, liver-derived dECM was used as bioink. Rheological and biochemical 
characterizations, as well as its support for cell viability and differentiation, were tested, and 
the bioink  was proven to be useful for tissue engineering applications [63]. Korean domestic 
pig skin-derived dECM was used for evaluation of a novel bioprinter and the effects of the 
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printing method on the printed structure. The physical properties of the bioink and cell viability 
were evaluated [64]. 
dECM lacks the mechanical properties of synthetic biomaterials as it goes through 
decellularization. Previously, the mechanical strength of dECM has been tried to be increased 
by additives such as vitamin B2 to heart derived dECM [65]. Another approach for increasing 
the mechanical properties of dECM bioink is blending it with conventional biomaterials. dECM 
has great potential to be used as blends with other materials. Since synthetic biomaterials lack 
bioactive properties and some of the natural biomaterials such as alginate and agarose are 
bioinert, combining these materials with dECM gives them required bioactive properties. At 
the same time, the presence of conventional material provides mechanical strength to the hybrid 
material [66], [13]. For example, in order to increase the cell attachment and migration of 
alginate, vascular tissue derived dECM was mixed with alginate and bioprinted to create 
blood vessel constructs. Cell proliferation, viability and differentiation evaluations showed 
that hybrid bioink had better properties than alginate bioink [67]. dECM hybrid bioinks are 
considered scalable as well as affordable when they are used as blends with other low-cost 
biomaterials [13].  
The motivation of this thesis work is to develop a blend of cell sheet derived decellularized 
extracellular matrix with a conventional biomaterial, agarose for the production of a novel 
hybrid bioink for 3D bioprinting applications.  
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2. EXPERIMENTAL 
2.1. Fibroblast Cell Culture 
NIH 3T3 murine embryonic fibroblast cells (ATCC) were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
supplement, referred as complete medium.  
To start the culture, cells were taken from the cryogenic storage tank, thawed rapidly at 37 °C 
water bath with rapid shakes. The melted components were transferred into 15 ml falcon tube 
containing a complete medium for centrifugation. Centrifugation was done at 2500 rpm for 5 
minutes. After centrifugation, the supernatant was removed, the cell pellet was resuspended 
with 1 ml of complete medium, homogenized by aspiration and extrusion with a pipette. The 
suspension of cells and complete medium was transferred into 25 cm2 tissue culture flask 
containing 4 ml of complete medium, pre-heated in the incubator. The cells were observed 
under a light microscope and cultured in an incubator at 37 °C with 5% CO2. The medium was 
changed every three days, and the passage was done when cells reached confluency at around 
85%. For passaging, the medium was emptied from the flask by aspiration, the flask was 
washed with PBS, and 3-4 ml of 0.25% trypsin-EDTA was added to the flask. The flask was 
kept in the incubator at 37 °C with 5% CO2 for 4-5 minutes, the detachment of cells from the 
flask surface was controlled with the naked eye as well as under the light microscope. 3-4 ml 
of fresh medium was added to the flask, and the surface of the flask was washed in order to 
detach all of the cells. The suspension was transferred into a 15 ml falcon for centrifugation at 
2500 rpm for 5 minutes. After centrifugation, the supernatant was removed, the pellet was 
resuspended with fresh medium, and the content was transferred into the new flask to continue 
cell culturing or to the six well plate for cell sheet production. 
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2.2. Fibroblast Cell Sheet Culture 
NIH 3T3 cells (ATCC) with passage number between 10 and 12 were seeded on the six well 
plates with a density of 8000 cells/cm2 as can be seen in Figure 6(a). The cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) with 20% fetal bovine serum (FBS), 20% Ham 
F12 medium, 500µM of ascorbic acid and 1% penicillin/streptomycin supplement. The cells 
were incubated at 37 °C with 5% CO2. The medium was changed every three days, and the cells 
were allowed to proliferate for five weeks until their self-detachment from the surface of the 
plate as can be seen in Figure 6(b) and 6(c). 
 
Figure 6: Fibroblast cell sheet culture (a) 3T3 fibroblast cells were seeded with 8000 
cells/cm2 density in 6 well plates, (b) Cells were cultured for five weeks, (c) After five weeks 
cell sheets detached from the surface 
 
 
 
(b) (c)(a)
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2.3. Preparation of Decellularization Agents 
First decellularization solution including 1 M NaCl, 10 mM Tris, 5 mM EDTA was prepared 
by dissolving all components in 1 liter of distilled water and mixing for 30 minutes at 500 rpm. 
NaCl and Tris were added for osmotic shock treatment while EDTA was used for weakening 
the cell-cell adhesion. Second decellularization solution was prepared by dissolving 0.5 wt% 
SDS, 10 mM Tris, 25 mM EDTA in PBS and mixing at 500 rpm. SDS was used for 
solubilization of nuclear and cytoplasmic membranes as well as removal of DNA. 
2.4. Decellularization of Fibroblast Cell Sheets 
The cell sheets were decellularized after their self-detachment from the six well plate surface. 
The medium was aspirated, the first decellularization solution was added, and the plates were 
shaken at 75 rpm for 1 hour on a plate shaker at room temperature. After this step, the cell 
sheets were rinsed with PBS 3 times for 10 minutes at 75 rpm on a plate shaker. Second 
decellularization solution was added after the careful removal of PBS. The system was shaken 
for 30 minutes at 75 rpm, at room temperature. Another PBS wash step was applied, three times 
for 10 minutes at 75 rpm. The cell sheets were rinsed in DMEM with 20% FBS for 48 hours at 
room temperature at 75 rpm. The final PBS wash step was applied, for three times for 10 
minutes. The obtained decellularized extracellular matrix (dECM) structures were stored in 
PBS at 4 °C. 
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2.5. Evaluation of Decellularization Protocol 
2.5.1. Genomic DNA assay 
 
The genomic DNA content of both decellularized and non-decellularized ECM samples was 
measured. DNA was isolated from both samples using QIAamp Fast DNA Tissue Kit. The 
protocol provided by the supplier was followed with minor changes based on the requirements 
of our work. First, the samples were freeze-dried for two days at -111 °C and 0.001 hPa in 
Scanvac CoolSafe Freeze Dryer. 6 mg of dECM and control (non-decellularized ECM) were 
weighted. The master digestion buffer including 200 µl AVE, 40 µl VXL, 1 µl DX Reagent, 20 
µl Proteinase K, 4 µl RNase A (100 mg/ml) per sample was prepared. Master digestion buffer 
was added on samples and was vortexed for 5 minutes at full speed. No residual particles were 
left after this step. Then, the samples were incubated at 56 °C for 10 minutes in thermomixer at 
1000 rpm. 265 µl Buffer MVL was added to both samples and mixed by pipetting. The 
impurities and proteins were washed off with multiple washing steps with the addition of Buffer 
AW1 followed by centrifugation and Buffer AW2 addition followed by centrifugation. After 
each step, the filtrate was discarded. On the final step of washing, 50 µl ATE was added on the 
samples which were in 1.5 ml sterile Eppendorf tubes, incubated for 1 minute at room 
temperature and centrifuged for 1 minute. The concentration of DNA in both samples were 
measured using NanoDrop 2000c in pedestal mode. Elution buffer was used as a blank solution. 
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2.5.2. DAPI staining 
In order to evaluate the removal of nuclear content, dECM structures were stained with 4’,6-
diamino-2-phenylindole (DAPI). The ECM structures that have not been decellularized were 
also stained for control purposes. 
The samples were fixed with 4% paraformaldehyde solution (v/v, in PBS) for 10 minutes at 
room temperature in the chemical fume hood. The structures were washed with PBS 3 times. 
The staining procedure was started with the permeabilization of the structures in 0.1 % Triton 
X-100 (v/v, in dH2O) for 15 minutes at room temperature. After this step, the structures were 
incubated with DAPI stain prepared by 1:500 dilution of the 1 mg/ml stock solution in 1x PBS. 
The staining was done for 30 minutes at room temperature on a shaker. After staining, the 
stained structures were washed three times with PBS for 5 minutes on a shaker. The 
preservation of the structures was achieved with Vectashield mounting medium addition. 
Storage was done at 4 °C. The microscopy observations were conducted with Zeiss LSM 710 
Confocal Microscope. 
2.5.3. F-actin immunostaining 
Cytopainter F-actin staining kit was used for immunostaining of both decellularized and non-
decellularized ECM samples. Fixation and permeabilization of the samples were done as 
explained in the previous section. 1 µl of the red fluorescent phalloidin conjugate was diluted 
with 1 ml of labeling buffer and added to the samples. The samples were shaken in the solution 
for 30 minutes at room temperature. The samples were washed with PBS 2-3 times for 2-3 
minutes. The stained samples were analyzed with Zeiss LSM 710 Confocal Microscope. 
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2.6. Characterization of dECM 
2.6.1. Collagen I immunostaining 
The collagen I immunostaining was done on decellularized and not decellularized ECM 
samples in order to observe the collagen content of both samples. The cells were fixed as 
discussed in the previous sections. Blocking was accomplished by incubating the samples in 
3% bovine serum albumin solution (in PBS) for 90 minutes at 40 °C. Primary antibody for 
collagen I immunostaining was prepared with 1:500 dilution in 3% bovine serum albumin 
solution (in PBS). The samples were incubated with primary antibody solution at 4 °C for 12 
hours. After this incubation, the samples were washed with PBS 2 times for 5 minutes. 
Secondary antibody (Alexa Fluor 488 conjugated goat anti-rabbit) solution was prepared as 
discussed for the primary antibody. Samples were incubated in this solution for 1 hour at room 
temperature and washed with PBS 2 times for 5 minutes. Tiled z-stack images and snap images 
of the stained samples were captured with Zeiss LSM 710 Confocal Microscope.  
2.6.2. Fourier-Transform Infrared (FT-IR) spectroscopy analysis 
FT-IR analysis was carried out on both decellularized and not decellularized ECM samples as 
well as SDS powder in order to show the content of both samples and the removal of the SDS 
used during decellularization. The removal of toxic SDS is crucial and needs to be proven 
before progressing into next stages of ECM processing. The FT-IR analysis is also used for 
observation of the effects of decellularization protocol on the protein structure of the 
extracellular matrix. 
Both decellularized and not decellularized ECM samples were freeze-dried before FT-IR 
analysis. Initially, the samples were kept at -80 °C overnight. Then, the samples were dipped 
into liquid nitrogen for decreasing their temperature and the freeze-drying was accomplished at 
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-111 °C and 0.001 hPa for two days in Scanvac CoolSafe Freeze Dryer. Freeze dried samples 
were analyzed with FT-IR or stored at -20 °C for further use. 
FTIR was done in Attenuated Total Reflection (ATR- FTIR) mode, using Thermo-Fischer 
Nicolet iS10 FT-IR Spectrometer. The absorbance from the air was collected before sample 
analysis and subtracted from the sample results as background removal. The scan number was 
set as 128 where the resolution was set as 4.  
2.7. Preparation of dECM Hydrogel 
 
2.7.1. Solubilization of dECM powder 
 
dECM powders were obtained by freeze-drying for two days at -111 °C and 0.001 hPa in 
Scanvac CoolSafe Freeze Dryer as can be seen in Figure 7(a). The rest of the experiments were 
all done in safety cabinet, and UV sterilization was used before experiments for the sterilization 
of both the safety cabinet and the equipment such as tweezer, scissor, plate heater. 
Solubilization of the dECM powder was done by partial enzymatic digestion at an acidic 
environment. The collagen fibers were digested with the enzymatic activity of pepsin enzyme 
into smaller sections by hydrolyzing the peptide bonds. For this purpose, pepsin solution was 
prepared by adding pepsin powder from porcine gastric mucosa in 0.01 M HCl with a final 
concentration of 1 mg/ml. The pH of the solution was measured to be 2 where pepsin shows 
maximum proteolytic activity for the digestion of collagen. dECM powders were added in the 
pepsin solution with 10 mg dECM/mL pepsin solution concentration and were digested for 26 
hours by stirring at 700 rpm at room temperature as can be seen in Figure 7(b). The digestion 
time was set for 26 hours where the sufficient digestion of the collagen fibers was achieved, 
and the excessive digestion was avoided. At the end of digestion, a flowable solution was 
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obtained as can be seen in Figure 7(c). The solution was stored at 4 °C for maximum one week 
or was used for neutralization. 
 
Figure 7: Steps of production of dECM gel (a) The dECM powder was obtained after freeze 
drying, (b) The dECM powder was digested with pepsin solution for 26 hours, (c) The 
digested dECM after 26 hours 
 
2.7.2. Neutralization and sterilization of dECM solution 
 
The digested ECM powders were pH and salt neutralized in order to initiate gelation kinetics 
before their use as bioink. All of the neutralization agents were stored at 4 °C before using them 
and the neutralization was done on ice to avoid the rapid gelation of the material. The pH 
neutralization was achieved by the addition of 0.1 M NaOH solution in the dECM digest in a 
drop by drop manner until the pH was 7.5. The pH was measured with a pH indicator after the 
addition of the NaOH solution. At this pH, the proteolytic activity of pepsin is stopped 
irreversibly, and the progress to next steps as neutralization and cell encapsulation can be done 
without and negative effects. The salt neutralization was obtained by addition of 10x PBS in 
(a) (b) (c)
 31 
the solution with the final concentration of 1x. The sterilization of the material was done by 
addition of  1% penicillin-streptomycin in the PBS solution used for salt neutralization. 
2.8. Preparation of Cell Laden dECM- Agarose Hybrid Bioink 
 
dECM solution obtained after digestion and neutralization steps was mixed with 3% (w/v) 
agarose solution in 1:10 (v/v) ratio. The mixing was done at 38.5 °C to avoid gelation of the 
materials before printing. NIH 3T3 cells were cultured as discussed in the previous sections. 
The cells were mixed with agarose with 4.5x105 cells/ml final concentration. For the mixing of 
cells with agarose, cells were centrifuged in Eppendorf, the supernatant was discarded, and 
agarose was added on the cells by micropipette. This mixture of cells and agarose was mixed 
with dECM gel with the specified ratio and kept at 38.5 °C during printing. The additions and 
mixing were done without aspiration and extrusion to avoid creation of bubbles in the bioink. 
The mixing was done with 200 µl pipette tip manually. 
As a control group, 3% (w/v) agarose solution was used. Due to the advantages of agarose such 
as being bioinert and affordable, possessing good printability and gelation, the ability to 
crosslink thermally and good printability, it was used in the blend bioink with dECM. 
Therefore, it was also used as the control group. This solution was prepared by addition of 1.5 
g agarose powder into 50 ml of 1x PBS and autoclaving at 115 °C for 15 minutes. By 
autoclaving, the powder was dissolved in the PBS and also, the sterility of the solution was 
achieved. Agarose solution was prepared on the day of bioprinting and was not stored for a long 
time before printing to keep its properties unchanged. The same ratio of 3T3 cells was added in 
the agarose solution and printed under the same conditions as the hybrid bioink. 
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2.9. Bioprinting of Cell Laden dECM- Agarose Hybrid Bioink 
 
For printing, an extrusion-based bioprinter, Organovo which can be seen in Figure 8 was used. 
The bioink was kept at 38.5 °C during printing and this temperature was continuously controlled 
with thermocouple to avoid decreasing in the temperature which could lead to gelation of the 
bioink before printing. The code needed for bioprinting was prepared according to the needs of 
this bioprinting. Initially, the zero point was set by moving the capillary in x, y and z-axes. 
Then, the bioink was aspirated from the bioink chamber with 1.5 cm length and 2 mm/s rate 
through a capillary with 450 µm inner and 500 µm outer diameters. Then, the bioink was chilled 
in 4 °C 1x PBS for 10 seconds in order to initiate gelation.  
 
Figure 8: Organovo bioprinter parts shown 
 
 
 
 
 
Gel printing headCell printing head
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The bioprinting step is explained in detail in Figure 9. Firstly, the hybrid bioink that is kept in 
the bioink reservoir at 38.5 °C is aspirated with the help of the glass capillary and the moving 
plunger inside the capillary as can be seen in Figure 9 (a), (b) and (c) respectively. The bioink 
is then printed on the printing stage in stripes. The schematic figure shows printed blend dECM  
bioink in Figure 9 (d). 
 
Figure 9: Bioprinting steps explained (a) System elements shown, (b) Capillary and plunger 
enters the bioink reservoir, (c) Aspiration of the bioink, (d) Bioprinting on the printing stage 
 
Bioprinting of the hybrid bioink was done on agarose surface for better structural integrity and 
attachment to the surface as can be seen in Figure 10. The integrity of the products was 
preserved after bioprinting showing the ability of the material to be successfully bioprinted. 
Integrity preservation is a good indicator for understanding the printability of the material. After 
(a) (b) (c) (d)
Plunger
Printing stage
Bioprinted stripe
dECM content
Glass capillary 
Bioink reservoir
Hybrid Bioink
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bioprinting, the complete medium for cell culture was added on the samples, and the samples 
were taken to the incubator at 37 °C with 5% CO2 level for incubation. 
 
 
Figure 10: Bioprinted structures (a) Single stripe, (b) Three stripes printed next to each other 
 
 
2.10. Live/Dead Assay 
 
The viability of encapsulated cells in the samples was tracked and observed 0, 1, 3 and 7 days 
after the bioprinting with Live/Dead fluorescence assay. For this purpose, both dECM-agarose 
bioink and only agarose bioink samples were stained with Calcein AM and Propidium Iodide 
(PI). Calcein AM which was prepared by diluting a 1mg/ml stock solution in 50 µl DMSO in 
dark conditions was used for detecting the living cells where PI was used for detecting the dead 
cells. 
2 µl Calcein AM was added in 3 ml growing medium in which the samples were and incubated 
for 45 minutes in the incubator at 37 °C with 5% CO2. After incubation, the samples were 
washed with 1x PBS at room temperature. Then, 2.5 µl PI was added to 3 ml of PBS which the 
(a) (b)
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samples were in. The samples were incubated in the incubator at 37 °C with 5% CO2 for 15 
minutes. The stained samples were always kept in the dark, covered with aluminum foil. 
As the samples were printed on a thin layer of agarose on the glass surface of 35 mm petri dish, 
the confocal microscopy imaging was conducted with the same dishes without the need for 
transferring the samples from printing dish to microscopy dish. Z stack images of the samples 
were taken with a Zeiss LSM 710 confocal microscope. 
Quantification of the Live/Dead Assay was done by using Image J. The living, and dead cells 
were counted separately, the ratio of the living cells to the number of cells was calculated. These 
values were used as percentages and were used for understanding the cell viability. 
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3. RESULTS & DISCUSSIONS 
3.1. Fibroblast Cell Sheet Culture and Decellularization of Fibroblast Cell Sheets  
Cell sheets were cultured as discussed in the previous section and the detachment of sheets from 
the well plate surface was observed after five weeks of culturing. This period is shorter than 
what was observed in previous studies where PDMS was used as surface coating, and sheets 
were removed after six weeks of culturing [68]. Cell sheet detachment did not only happen in 
a shorter period but also required no external interference such as temperature change or 
enzyme treatment. This self-detachment is beneficial for the conservation of the integrity of the 
ECM structure. 
SDS was selected as the decellularization agent as it was proven to be efficient in the removal 
of nuclear and cytoplasmic DNA. Decellularization of the cell sheets was accomplished by 0.5 
wt% SDS containing solutions as this SDS percentage was described as high SDS 
concentration, 0.05 wt% SDS being the low SDS concentration, in the previous studies and 
proven to be leading to a more efficient DNA removal [68]. The addition and removal of all 
decellularization agents and PBS were done gently to reduce the harmful effects on the samples. 
During decellularization and washing steps, the samples were shaken at 75 rpm which is below 
the critical level of 100 rpm. Higher agitation speeds were proven to be harmful to ECM 
structure [36]. 
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3.2. Evaluation of Decellularization Protocol 
3.2.1. Genomic DNA assay 
 
Decellularization efficiency was evaluated with Genomic DNA assay. The DNA content of two 
samples decellularized ECM (dECM) and non-decellularized ECM (control), were measured 
and the ratio of removed DNA content was used as an indicator for efficient decellularization. 
In Figure 11 the DNA content of the control group is taken as 100% and compared to the 
decellularized ECM sample. The remnant DNA content in dECM sample is 18,9% which 
indicates 81,9% of the genomic DNA was removed with the decellularization protocols applied 
to the samples. These values show that the decellularization protocols were able to reduce the 
DNA content significantly when compared to the control group [69]. 
 
Figure 11: The DNA content comparison between non-decellularized samples (control) and 
decellularized samples (dECM) 
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3.2.2. DAPI staining and F-actin immunostaining 
F-actin and DAPI staining were used for observing the structure of the cell sheets produced as 
can be seen in Figure 12. DAPI staining and F-actin immunostaining images also showed the 
removal of cell nuclei and F-actin structure in decellularized samples. As can be seen in Figure 
13, while the cell sheet that has not been decellularized (control group) had clear DAPI (blue) 
and F-actin (red) signals, these signals were not obtained from decellularized cell sheet 
structures, indicating the devoid of cell nuclei and F-actin structure, respectively. In Figure 12, 
(a) shows the DAPI stained cell nuclei of the control group, (b) shows the F-actin structure of 
the control group where (c) is the merged image of both staining methods for the control group. 
In the lower row, the images of decellularized cell sheet are presented. No signals were obtained 
from DAPI staining and F-actin immunostaining of decellularized cell sheet structures as can 
be seen in (d) and  (e) respectively. For observations of decellularized and not decellularized 
structures, the same digital gain inputs were used in order to have consistency among 
experiments.  
 
Figure 12: Cell sheet structure observed after DAPI and F-actin staining 
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Figure 13: DAPI and F-actin staining of both decellularized and non-decellularized samples 
(a) DAPI staining for control sample, (b) F-actin staining for control sample, (c) Merged 
image for control sample, (d) DAPI staining for dECM sample, (e) F-actin staining for dECM 
sample, (f) Merged image for dECM sample 
3.3. Characterization of dECM 
3.3.1. Collagen I immunostaining 
Previous studies have proven that the most abundant protein of ECM is collagen [6]. Collagen 
I immunostaining was carried out in order to show this on both decellularized and not 
decellularized (control) samples of ECM. The collagen content was shown qualitatively on both 
samples as can be seen in Figure 14. In the upper row of Figure 14, the DAPI (blue) and collagen 
(a) (b) (c)
(d) (e) (f)
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(green) staining of the control group can be seen. The lower row shows the DAPI and collagen 
staining images of the decellularized ECM sample. As can be seen in (d), the cellular content 
is removed by decellularization successfully whereas (e) shows the conservation of the collagen 
content after decellularization. Figure 15 provides cross-sectional observations of both 
decellularized and non-decellularized cell sheets. As can be seen, the collagen content is 
preserved while the cells are removed after decellularization. The thickness of the samples are 
similar; the variations might be due to the regional folding of the sheet structure during staining 
and washing steps. 
 
Figure 14: Collagen and DAPI staining of control and dECM samples (a) DAPI staining for 
control sample, (b) Collagen staining for control sample, (c) Merged image for control 
sample, (d) DAPI staining for dECM sample, (e) Collagen staining for dECM sample, (f) 
Merged image for dECM sample 
(a) (b) (c)
(d) (e) (f)
 41 
 
Figure 15: Cross-sectional images of DAPI and collagen staining (a) For control sample (b) 
for dECM sample 
3.3.2. Fourier-Transform Infrared (FT-IR) spectroscopy analysis 
In the FTIR analysis results, there were two main objectives. First one was to detect the absence 
of SDS in the decellularized samples in order to show the removal of decellularization agents 
was successful. SDS has sulfate groups which give characteristic peaks at 1247 cm-1 as we 
could see from FTIR results for the SDS powder in Figure 16. We expected not to see this 
shoulder in the dECM spectrum. As can be seen in Figure 17 and 18, there is no shoulder at  
1247 cm-1 which means the SDS was successfully removed from the samples after 
decellularization. As SDS is a highly toxic material and affects the cell viability, excessive 
washing was applied to the samples for the removal of SDS. Therefore, it was crucial to show 
the removal of SDS from the samples. 
(a)
(b)
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Figure 16: FTIR spectrum for SDS 
 
Figure 17: FTIR spectrum for decellularized ECM (dECM) 
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Figure 18: FTIR spectra of SDS and dECM, merged (blue line represents dECM sample, 
green line represents SDS sample) 
Secondly, the conservation of ECM structure after decellularization was inspected. The 
collagen b-sheet and triple helix structures were expected to be conserved after 
decellularization. In order to observe this conservation, non-decellularized ECM (control) and 
decellularized ECM (dECM) samples were compared. As can be seen in Figure 19, the 
characteristic peak at 1632 cm-1 was observed in both samples meaning that the collagen content 
was conserved after decellularization. 
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Figure 19: FTIR spectra of dECM and ECM control merged (blue line represents dECM 
sample, red line represents control sample) 
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3.4. Live/Dead Assay 
 
The viability of 3T3 cells in both decellularized ECM-agarose-cell bioink and agarose-cell 
bioink (control) were evaluated 0, 1 and 7 days after the bioprinting.  
The 0-day imaging was done 4 hours after the bioprinting. As agarose-cell blend was prepared 
by aspiration and extrusion with a micropipette, cells were homogenized better than the dECM 
sample where the cells were mixed in the solution by manual shaking in order to avoid bubble 
formation. The cell viability assay 4 hours after bioprinting showed no major difference 
between the control group and the dECM group as can be seen in Figure 20. One day after the 
bioprinting, cell viability assay was done as can be seen in Figure 21. Both of the samples had 
a higher ratio of dead cells compared to day 0. There was no problem of homogenous cell 
dispersion. As can be seen from Figure 22, Day 7 viability test showed that one week after the 
bioprinting, the cells in the dECM bioink showed similar cellular viability as the control group. 
The cells were able to attach to the material without loss of cellular viability. The high viability 
seen in dECM bioink samples also indicate the successful removal of SDS after 
decellularization as the presence of any remnant SDS would cause sudden death of cells. This 
result matches the results of FTIR analysis. The high viability of dECM bioink also indicates 
that the neutralization after pepsin digestion was completed successfully as the acidic 
environment is deadly for cells and if the pH were not neutralized, the cells would not show 
such viability. 
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Figure 20: Live/Dead Assay Day 0, (a) control (b) dECM 
 
 
Figure 21: Live/Dead Assay Day 1, (a) control (b) dECM 
 
(a) (b)
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Figure 22: Live/Dead Assay Day 7, (a) control (b) dECM 
 
 
The quantification of the Live/Dead assay showed that the cell viability of agarose control and 
the dECM- agarose hybrid bioink samples were very close 4 hours after bioprinting. The same 
results were achieved for day 1 and day 7 experiments. These results in Figure 23 showed the 
ability of dECM hybrid bioink to support the cellular viability was quite similar to the ability 
of agarose. The dECM bioink was able to support the cell viability, and it did not possess any 
toxic effect on the cells. 
 
 
 
Figure 23: Quantification of Live/Dead Assay Results 
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4. CONCLUSION AND FUTURE WORK 
 
The purpose of this thesis work is to produce a novel bioink which can overcome the problems 
faced by the current bioinks used for 3D bioprinting applications. For this purpose, a 
commercially available and easily printed material agarose was blended with extracellular 
matrix (ECM) obtained from cell sheet culturing. The cell sheets were cultured on polystyrene 
surface, and the detachment of the sheets was done with no enzymatic or thermal application 
which helps to protect the integrity of the ECM structure. Also, the cell sheets were cultured 
for five weeks which is a shorter period than the ones present in the literature. 
After self-detachment of the cell sheets, the cellular content of the structure was removed in 
order to avoid unwanted host responses. For this purpose, chemical and biological agents were 
used. The removal of cellular content, DNA as well as the decellularization agents was 
evaluated and found to be successfully removed which leads to the next steps of bioink 
production. 
Once decellularized extracellular matrix (dECM) was proven to be safe for use, it was freeze-
dried into powder form, solubilized by enzymatic digestion and neutralized based on pH and 
salt content for providing a suitable environment for cells. The dECM gel was mixed with 
agarose and 3T3 cells to complete the hybrid bioink structure and printed with an extrusion-
based bioprinter. The printed structures were incubated for a week with medium changes every 
3 days for longer incubation and cell viability was evaluated 0, 1 and 7 days after bioprinting. 
The live/dead assay showed similar cellular viability among the control group and the dECM 
hybrid bioink showing the success of the blend bioink to support the cellular viability and 
causing no toxic effects.  
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As a future work, the dECM gel could be mixed with other hydrogels for creating different 
bioinks. The effect of this bioink on stem cell differentiation could be evaluated by 
encapsulating the cells in the bioink or by using the dECM material as a surface coating. The 
homogenization of the cells in the bioink is an important step that needs to be improved so both 
samples can be homogenized at the same quality. Other cell types such as human dermal 
fibroblast cells could also be used for the preparation of cell sheets in order to understand the 
effect of the cell line on the properties of ECM. Cell modifications could be evaluated for its 
possible effects on the structure, amount of ECM as well as the glycosaminoglycan content of 
the ECM.  
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